BioMed Taiwan Features Custom Silicon Chips, Micromachines, and Healthcare Robotics at Luncheon at RESI on Jan. 8th

13 Dec

By Jessica Yang, Senior Investor Research Analyst & Asia BD, LSN

As more and more Asia-based companies are trying to enter the global market, RESI provides the stage for these companies to shine. This year, we are partnering with BioMed Taiwan to launch a luncheon at RESI JPM from 11:50 am – 1:00 pm at Marines’ Memorial Club & Hotel (2nd floor), and you are invited to attend! This will be a great opportunity to network with international hubs and investors and explore the latest cutting-edge technologies from Taiwan. RSVP now to join the Taiwan Luncheon!

LOCATION:

Marines’ Memorial Club & Hotel 2nd floor Theater, 609 Sutter St, San Francisco, CA 94102

DATE AND TIME:

01/08/19 11:50am – 01/08/19 1:00pm

**Check out the presenting Taiwan companies below:

Acusense has developed a patch-sensor technology that can detect leakage of intravenous devices such as drug delivery or dialysis. This type of complication can lead to sever injury or death, and there has been no good system to detect leakage to date. Acusense’s technology is incrementally superior to its single competitor on the market.

A novel approach to monitorization in Critical Care and the OR which uses sound to address the problem underdiagnosis of lung-related complications. The technology detects sounds in the chest that can indicate certain complications that could be life-threatening and that would otherwise go undetected, and alerts staff at the monitoring station.

Above Care is developing a sensor-device to detect complications on venous shunts used in patient groups that require a permanent venous access, namely diabetics. Stenosis is a common issue for this patient group and can be resolved in a cost-effective manner when detected early, which avoids costly emergency surgery.

PressureDot is a novel medical device which is swallowed by the patient and is able to accurately and continuously monitor intrabdominal pressure to help diagnose sever conditions like pancreatitis and potentially lower the high associated mortality rates.

Preclinical development of selective HDAC6 inhibitor, MPT0G211 and Phase II clinical development of pan-HDAC inhibitor, MPT0E028 for solid tumors and various neurodegenerative disorders.

WeMED is developing a light-based technology to address the unmet need of distal interlocking of intramedullary nails for the treatment of fractures of long bones. Current procedures for this indication have major drawbacks, and WeMED’s solution is both simple and effective.

Point Robotics is developing a navigation and robot-aided surgery platform for use in high-risk surgical applications, beginning with spine surgery. It is unique in that it is a hand-held device that provides both accuracy and pressure sensing technology. The approach is also unique in that it permits minimally invasive robotic-guided surgery (MIS) and minimal radiation exposure.

AllBio Life is developing a next-generation gene sequencing technology that will provide precision medicine recommendations to caregivers in order to prescribe the right drugs in the right dose at the right time, by predicting patient response to different therapy options. The clinical recommendations will include guidelines for other factors like nutrition. They are also developing a digital health platform for patient management (drugs, lifestyle, nutrition, etc.).

Taipei Bio is developing tissue regeneration technology that is incrementally superior to products on the market today. In comparison to the most widely used bone substitute products containing Demineralized Bone Matrix (BMP), Taipeibio’s products contain no cytokines, associated with increased risk of cancer. The use of this technology for cartelage repair would address an untapped market worth billions.

Ultron is developing a robot-like device that aims to compliment care for the elderly, both in the hospital setting and in the home, by engaging patients using voice recognition technology and interacting in activities like exercise, taking meds, games for mental acuity and direct communication with care providers or family members.

An unique innovation joining hollow fiber assay with novel Microtube Array Membrane providing unprescendented accuracy and cost reduction compared to patient-derived xenograft for personalized cancer treatment and oncological drug R&D.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: